Dolly Sud writes her debut elf blog on a recent retrospective analysis, which compares dose changes of risperidone and aripiprazole with patients’ individual genotype.
[read the full story...]
Peter Haddad and Sami Ouanes review a network meta-analysis of the impact of antipsychotic drugs on metabolic function in people with schizophrenia.
[read the full story...]
Keith Laws looks at a systematic review of patient and study characteristics, which asks: are randomised controlled trials on pharmacotherapy and psychotherapy for positive symptoms of schizophrenia comparable?
[read the full story...]
Emmeline Lagunes Cordoba and Derek Tracy explore a case control study that looks at cognitive change in people with schizophrenia and other psychoses in the decade following the first episode.
[read the full story...]
Deenan Edward and Suhana Ahmed summarise a Scottish study of prescribing for bipolar disorder between 2009-2016, which identified a clear trend towards decreasing lithium use.
[read the full story...]
Lina Gega from the Closing the Gap Network explores a recent review of digital technology for health promotion, which looks at opportunities to address excess mortality in people living with severe mental illness.
[read the full story...]
Syeda Akther writes her debut elf blog on a recent review looking at racial disparities in bipolar disorder treatment and research. She argues that we need to start having serious conversations about racism that go beyond unconscious bias.
[read the full story...]
Dean Connolly looks at an international study which asks: Is there consensus across evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period?
[read the full story...]
Carla McEnery summarises a systematic review and meta-analysis of interventions and social functioning in youth at risk of psychosis.
[read the full story...]
Ben Janaway writes his debut elf blog on the STEPWISE RCT which is out today in the British Journal of Psychiatry: Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis.
[read the full story...]
